If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() International Journal of DermatologyVolume 38 Issue 8, Pages 601 - 603 Published Online: 25 Dec 2001 Journal compilation © 2010 International Society of Dermatology The Official Journal of the International Society of Dermatology
Abstract | References | Full Text: HTML, PDF (Size: 149K) | Related Articles | Citation Tracking CLINICAL TRIAL Fluconazole vs. Itraconazole in the treatment of tinea versicolor Copyright 1998 Blackwell Science Ltd ABSTRACTNinety patients with tinea versicolor were randomly assigned to treatment with either a single 450-mg dose of fluconazole, two 300-mg doses of fluconazole given 1 week apart, or itraconazole 200 mg daily for 7 days. At the end of treatment, the cure rate for itraconazole (20%) was significantly higher (P = 0.024) than that for fluconazole 450 mg (0%). When cure plus improvement was considered, response rates among the three treatment groups were comparable (97, 100, and 97% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively). Failure rates at the end of treatment were low (0–3%). Clinical response rates achieved at the end of treatment generally were maintained at 1 month, but tended to decrease at 2 months. Eradication at the end of treatment was not significantly different among the treatment groups (17, 33, and 38% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively). At 1 month, the eradication rate was significantly higher (P = 0.012) for the two-dose than the single-dose fluconazole treatment group (97 and 70%, respectively). At 2 months, reinfection rates were 21, 20, and 4% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively. No clinical adverse events occured, and no patients were withdrawn for laboratory abnormalities. |